Glenmark Pharmaceuticals Ltd

- Glenmark Pharmaceuticals currently has no planned large stake sale in Glenmark Life Sciences to reduce debt; only a 7-8% sell-down is required by law, to be completed by August 2024. - The company expects to manage its upcoming $87.5 million settlement payment over two years through internal cash generation, not by increasing debt. - Management is focused on reducing gross and net debt levels, leveraging business growth and internal cash flow. - There has been no indication of new fundraising through equity. - Interest costs have increased mainly due to higher LIBOR rates rather than increased borrowing. - Overall, Glenmark aims to reduce debt internally without significant new external debt or equity fundraising in the near term.

- Glenmark Pharmaceuticals has planned consolidated CAPEX of Rs. 600 crore to Rs. 700 crore for FY'24. - Total asset addition in Q1 FY'24 was Rs. 127.5 crore, comprising Rs. 108 crore in tangible assets and Rs. 19.5 crore in intangible assets. - Strategic focus areas include investments in pipeline products in Respiratory, complex injectables, and Oncology assets (ICHNOS). - Continued R&D investment at around 8% to 8.5% of revenue, with ICHNOS investment at $17.2 million in Q1 FY'24. - Priority to free cash flow generation and closing at least one out-licensing deal in FY'24. - Remediation work related capex expected to incur minimal future costs. - Growth investments continue in key markets like Europe, U.S., and India, including upcoming product launches and scale-up in specialty areas.

- Glenmark expects consolidated revenue growth of 10% to 11% for FY'24. - The Europe business is a major growth driver with anticipated 25-30% growth this year and sustained 15-20% growth in the coming years. - The U.S. market is projected to grow in mid-single digits with around 8-10 new product launches planned this year. - India business is expected to grow in the single digits, with an 8% growth rate already recorded excluding divestments. - Ryaltris sales are ahead of guidance, expected to reach $40-45 million this year with potential to grow to $150 million over time. - New product launches in Respiratory, complex injectables, and other pipeline products are expected to fuel longer-term growth. - The company is optimistic about partnering assets like ISB 830 to enhance growth prospects.

- Glenmark aims consolidated revenue growth of 10-11% for FY'24. - Consolidated EBITDA margin is targeted at 19-20%+. - R&D investment is planned at 8-8.5% of revenue. - EBITDA for Q1 FY'24 was Rs. 631.2 crore with a margin of 18.6% (19% excluding FOREX loss). - Europe expected to grow 15-20% sustained basis; projected to be a $300 million business this year. - U.S. business targeting mid-single digit growth with stable pricing environment. - India business expected to grow in single digits after accounting for divestments and NLEM price impacts. - Pipeline products in respiratory, complex injectables, and other areas are key drivers for long-term growth. - Positive outlook on new product launches in the U.S. (8-10 launches planned in FY'24). - Increasing contribution of chronic therapeutic segments (47% contribution in India Q1) supports margin improvement. - Debt reduction is a key focus, supported by internal cash generation.

The transcript provided from Glenmark Pharmaceuticals Limited's Q1 FY'24 Earnings Call does not explicitly mention any details about the current or expected orderbook or pending orders. The discussion primarily covers topics such as: - Financial results and key business highlights for the quarter. - Remediation cost and related FDA warning letters. - Debt levels, repayments, and potential stake sell in Glenmark Life Sciences. - Sales performance in key markets such as Europe, India, and the U.S. - Pipeline updates including partnerships and product launches. - Growth outlook and strategy for different markets. No specific figures or commentary on orderbook or pending orders are disclosed in the available text.